Natasha B. Leighl MD, MMSc, BSc, FRCPC

Dr. Leighl is a medical oncologist at the Princess Margaret Hospital and an Associate Professor in the Department of Medicine at the University of Toronto. After receiving her MD from the University of Toronto, Canada, Dr. Leighl completed residencies in internal medicine at the University of Calgary and in medical oncology at the University of Toronto. She subsequently completed a Fellowship in Thoracic Oncology with Dr. Frances Shepherd at the Princess Margaret Hospital in Canada, a Fellowship in Clinical Oncology with Prof. Martin Tattersall at the University of Sydney in Australia, and received her MMSc in Clinical Epidemiology at the University of Newcastle, Australia.

Dr. Leighl’s main interest is in developing new treatments for lung cancer. She is involved in clinical studies of novel agents for the treatment of thoracic cancers, is a member of the Lung Disease Site Group Executive in the NCIC Clinical Trials Group. She is also Co-Chair of the NCIC CTG Committee on Economic Analysis. She has received an American Society of Clinical Oncology Career Development Award, ASCO Young Investigator Award, and IASLC Young Investigator Award for her work in developing treatment decision aids for patients with advanced lung, breast, and colorectal cancer. Dr. Leighl has served on several committees, including the ASCO International and Lung Educational Committees, the Royal College of Physicians and Surgeons of Canada Medical Oncology Examination Board, and the IASLC Career Development Committee. She is currently President of Lung Cancer Canada and has recently been awarded the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development at PMH/UHN/the University of Toronto.